GSK3B and Behcet disease: Interestingly, the study by Sakrajda et al. [127], which used the in vitro model of neuroinflammation with the microglia cell line (HMC3) and focused on NLRP3 inflammasome involvement in BD, showed that lithium treatment with concentrations similar to those observed in the brains (0.5 mM) with microglia induced with innate-immune cytokines caused a significant anti-inflammatory effect mediated via GSK-3β inhibition, which affected NLRP3 inflammasome priming; its activation; and as a result, IL-1β protein secretion [127].